| Jul 4 |
Broker Revenue Forecasts For 2seventy bio, Inc. (NASDAQ:TSVT) Are Surging Higher
|
| Jun 27 |
Novo Nordisk buys 2seventy bio’s Hemophilia A program
|
| Jun 26 |
2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million
|
| Jun 6 |
Goldman cuts 2seventy bio to neutral, cites competition concerns
|
| May 8 |
2seventy bio, Inc. (TSVT) Q1 2024 Earnings Call Transcript
|
| May 8 |
2seventy bio GAAP EPS of -$1.01 misses by $0.20, revenue of $12.4M misses by $1.69M
|
| May 8 |
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
|
| May 7 |
2seventy bio Q1 2024 Earnings Preview
|
| May 3 |
2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
|
